[EN] BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF [FR] DÉRIVÉ DE BENZIMIDAZOLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION MÉDICALE [ZH] 一种苯并咪唑类衍生物及其制备方法和医药用途
[EN] BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF [FR] DÉRIVÉ DE BENZIMIDAZOLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION MÉDICALE [ZH] 一种苯并咪唑类衍生物及其制备方法和医药用途
[EN] 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS<br/>[FR] DÉRIVÉS DE 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE ET COMPOSÉS ASSOCIÉS QUI SE FIXENT AU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE (S1P) DANS LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES
申请人:SERONO LAB
公开号:WO2009019167A1
公开(公告)日:2009-02-12
The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS
申请人:Merck Serono Sa
公开号:US20130109669A1
公开(公告)日:2013-05-02
The invention relates to compounds of formula (I):
wherein X, W, Q, R, R
1
and R
2
have the meanings given in claim
1
. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
One‐Carbon Ring Expansion of Indoles and Pyrroles: A Straightforward Access to 3‐Fluorinated Quinolines and Pyridines
作者:Huaixuan Guo、Shiqin Qiu、Peng Xu
DOI:10.1002/anie.202317104
日期:2024.1.25
1,1-Dibromoalkanes as bromocarbene sources make one-carbonringexpansion of indoles and pyrroles facile, allowing for direct access to structurally diverse azines, especially the pharmaceutically important 3-fluorinated quinolines and pyridines. This straightforward protocol features bench-stable reagents, a broad range of substrates, and good compatibility with various functional groups.